Navigation Links
Jennerex Appoints Lara Longpre to Chief Operating Officer
Date:8/25/2010

SAN FRANCISCO, Aug. 25 /PRNewswire/ -- Jennerex, Inc., a clinical-stage cancer biotherapeutics company, today announced the appointment of Lara Longpre to the position of chief operating officer. Ms. Longpre will be responsible for the development of the company's lead product, JX-594, as well as Jennerex's other product candidates in development and will lead the clinical operations and research, manufacturing, regulatory and quality functions. Ms. Longpre has served as a consultant to Jennerex since 2009.

"Lara's extensive experience in developing therapeutics will make her a key member of our executive management team," said David H. Kirn, M.D., president and chief executive officer of Jennerex. "Her systematic and meticulous approach to operations, combined with her demonstrated leadership ability, make Lara the ideal person to direct the development of JX-594 as we move toward late stage clinical trials in advanced liver cancer."

Ms. Longpre brings to Jennerex over 17 years of broad clinical research, operations, and leadership expertise in all stages of clinical development.  Prior to Jennerex, Ms. Longpre held the position of  senior vice president, clinical and corporate affairs at MedGenesis Therapeutix and held senior positions at PRA International, a global CRO, including vice president of proposals and contracts, vice president of quality and process management, director of global regulatory affairs, and director of operations. She has directly managed several pivotal Phase 3 trials, and has specific expertise in project management, clinical operations, and quality management systems, including achieving ISO 9001:2000 registration and ensuring Sarbanes-Oxley compliance while at an international CRO. Ms. Longpre holds an M.Sc. in Medical Science from Harvard Medical School, an MBA from Queens University, and B.A. from Cornell University.

About Jennerex

Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer.  The Company's lead product JX-594 is currently in two mid-stage clinical trials in patients with primary liver cancer—an international, randomized, Phase 2 dose-response clinical trial, and a Phase 2 study in combination with sorafenib.  Prior, published studies designed to establish dose levels and the safety profile of JX-594 have shown its ability to selectively target a variety of common cancer tumor types.  JX-594 and other product candidates under development are designed to attack cancer tumors through three diverse mechanisms of action: the lysis of cancer cells through viral replication, the reduction of the blood supply to tumors through vascular targeting and destruction and the stimulation of the body's immune response against cancer cells.  Jennerex is headquartered in San Francisco and has research and development operations in Ottawa, Canada and Pusan, South Korea.  For more information about Jennerex, please visit www.jennerex.com.


'/>"/>
SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
2. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
3. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
4. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
5. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
6. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
7. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
8. Jennerex Announces Presentations at Upcoming Conferences
9. Jennerex Appoints Gregory W. Schafer as Chief Financial Officer
10. Quark Pharmaceuticals Appoints New Chief Medical Officer
11. West Pharmaceutical Services, Inc. Appoints New Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... the ECG Cables And ECG Leadwires Market owing to the ... On the other hand, the Asia-Pacific ... during the forecast period. The market players namely, ... ( Ireland ), Koninklijke Philips N.V. ( ... China ), held major share of the ECG ...
(Date:12/2/2016)... 2, 2016 According to the latest ... Study on Automated Endoscope Reprocessors: Single Basin Automated Endoscope Reprocessors ... Between 2016 and 2024 " the global automated endoscope reprocessors market was valued ... expand at a CAGR of 7.2% during an eight-year forecast ... Mn by 2024. ...
(Date:12/2/2016)... , December 2, 2016 ... Vitro Diagnostics/IVD Market by Product (Instruments, Reagents, Software), ... (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) - Forecast ... is valued at USD 60.22 Billion in 2016. ... CAGR of 5.5% during the forecast period (2016-2021) ...
Breaking Medicine Technology:
(Date:12/4/2016)... Boca Raton, Fl (PRWEB) , ... December 02, ... ... a partnership that will give patients better access to nutraceuticals and help doctors ... to their EMR patient portal and practice management software platform for Integrative and ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... Body Shaping" at the 2016 Anti-Aging & Beauty Awards at The ... The Aesthetic & Anti-Aging Medicine European Congress (AMEC) brings together the industry’s ...
(Date:12/4/2016)... ... December 04, 2016 , ... Are You Concerned About Mold In Your Home ... Indoor Air Quality Companies in VA, MD and DC, recently completed its application for ... new mold law in the district of Columbia is a good thing stated John ...
(Date:12/2/2016)... ... 2016 , ... Two years ago, Arizona State University students ... by 1 million viewers and won numerous honors, including the region’s top Emmy ... Walter Cronkite School of Journalism and Mass Communication are following up their award-winning ...
(Date:12/2/2016)... ... December 02, 2016 , ... Advanced Inc., a leading provider of ... Bice, CPA, MBA to serve as Advanced Inc.’s Chief Financial Officer, effective December 1, ... Jason brings extensive financial and operational leadership experience to Advanced Inc. He began his ...
Breaking Medicine News(10 mins):